Global Measures | OMERACT Truth | OMERACT Discrimination | OMERACT Feasibility | ||||
---|---|---|---|---|---|---|---|
Face/Content Validity | Construct Validity | Reliability | Responsiveness | RCT | Score Interpretability | ||
WPAI (item 5) | ++ | ++ | + | ++ | ++ | + | ++ |
WPS-RA (item 4) | + | + | + | ++ | ++ | (+) | ++ |
+ | + | + | ? | + | + | ++ | |
HPQ (item A12) | ++ | ++ | + | ? | ? | (+) | ++ |
WAI (item 1) | ++ | ++ | + | ++ | ? | (+) | ++ |
Rating criteria (based on overall appraisal of all available evidence in arthritis or musculoskeletal conditions): For construct validity, reliability, and responsiveness: ++: Evidence of this measurement property from 2 or more studies, in the absence of conflicting evidence; +: Evidence of this measurement property from at least 1 study, and overall body of evidence supporting > refuting; +/−: Conflicting evidence available, current evidence does not meet ++ or +; −: Only negative evidence available; ?: No evidence available. For RCT: ++: 2 or more RCT providing evidence of discrimination (required for OMERACT endorsement); +: 1 RCT providing evidence of discrimination; (+): Ongoing RCT using worker productivity outcome measure (protocol available); −: Only evidence of lack of discrimination available; ?: No RCT available. Note: Discrimination includes between-group differences of within-group change, or between-group differences of final state. For score interpretability: ++: Estimates available from 2 or more studies; +: Estimates available from 1 study; (+): Estimates expected from an ongoing study; ?: Not yet available. RCT: randomized controlled trials.